Safe Orthopaedics obtains FDA approval to market its unique implant for Spinal Trauma care in the United States

Eragny-sur-Oise (France), October 13, 2015 – SAFE ORTHOPAEDICS (Euronext: FR0012452746 – SAFOR), a company developing and marketing an innovative range of sterile implants combined with their single-use surgical instruments, today announces that the U.S. Food and Drug Administration (FDA) has approved the marketing of Safe Orthopaedics’ new implant for repairing traumatic spinal injuries in the United States.

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the Company’s CE-marked and FDA-approved SteriSpine^TM kits are already being marketed in 12 countries, in Europe and the United States. They are being rapidly adopted by surgeons throughout the world, with nearly 1,000 procedures performed in 2014 and 1,143 in the first half of 2015 alone. The Company is based at Eragny‑sur‑Oise (France), and has 32 employees and a US subsidiary.

For more information, visit: www.SafeOrtho.com